A Study of RO5190591 (Danoprevir) in Healthy Volunteers
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This non-randomized, open-label study will evaluate the interaction of
RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability
in healthy volunteers. Participants will be administered repeated daily doses of ketoconazole
alone, RO5190591/ritonavir, and RO5190591/ritonavir plus ketoconazole. The anticipated time
on study treatment is 25 days.